雷替曲塞或氟尿嘧啶联合伊立替康二线治疗晚期结直肠癌疗效分析

目的 观察雷替曲塞或氟尿嘧啶联合伊立替康二线治疗晚期结直肠癌的近期疗效和不良反应。方法 对蚌埠医学院第一附属医院收治的52例经一线FOLFOX方案治疗失败的晚期结直肠癌患者进行二线治疗。A组（25例）化疗方案为雷替曲塞联合伊立替康，B组（27例）化疗方案为氟尿嘧啶联合伊立替康及亚叶酸钙，比较两组二线治疗的临床疗效、不良反应及生存情况。结果 A组和B组有效率分别为36%和11.5%，差异有统计学意义（P﹤0.05），疾病控制率分别为76.0%和57.7%，差异无统计学意义（P>0.05），中位疾病进展时间分别为6.0月和4.5月，差异无统计学意义（P>0.05）。结论 雷替曲塞联合伊立替康方案二线治疗晚期结直肠癌疗效肯定，不良反应能耐受，使用方便，值得临床上推荐使用。

Therapeutic Effect of Raltitrexed or Fluorouracil plus Irinotecan as Second-line#br# Treatment for Advanced Colorectal Cancer

Objective To evaluate the short-term efficacy and toxicity of raltitrexed or fluorouracil incombination with irinotecan as the second-line treatment for advanced colorectal cancer. Methods Totally52 advanced colorectal cancer patients with failed first-line chemotherapy were divided into two groups,Group A: 25 patients treated with raltitrexed plus irinotecan and Group B: 27 patients treated with irinotecanplus fluorouracil and leucovorin. The efficacy, toxicity and survival time of the treatments were comparedbetween two groups. Results The effective rates were 36.0% in Group A and 11.5% in Group B(P﹤0.05).The disease control rates were 76% in Group A and 57.7% in Group B(P>0.05). The median time to diseaseprogression were 6 months in Group A and 4.5 months in Group B(P>0.05). Conclusion Raltitrexedcombined with irinotecan is effective and safe as the second-line treatment for advanced colorectal cancer, andfurther clinical application is recommended.